

# OPTIMIZE FOR OUTCOMES WITH OMNIPOD® 5



Omnipod 5 real-world evidence demonstrated over

**80%** time in range (TIR) with optimized settings<sup>1</sup>

## Did you know?




**53%** of Omnipod 5 users not achieving glycemic targets **do not** frequently use the lowest Target Glucose setting of 110 mg/dL<sup>2</sup>

## TIR improvement as Target Glucose setting is lowered to 110 mg/dL

Real-world users **increased TIR by up to 12%** by switching from the highest to the lowest Target Glucose setting with **no clinically meaningful impact on time below range**<sup>3</sup>

Data shown as median. Results shown for users with ≥14 days of data and sufficient CGM data (users with ≥75% of days with ≥220 readings). \*p<0.05 comparing TIR in the first target period to the second period at the 110 mg/dL target.



1. Retrospective RWE data on file, 2025. Results shown for users with optimized settings including sufficient CGM data (≥75% of days with ≥220 readings), ≥90% time in Automated Mode, ≥5 bolus/day and an average Target Glucose of 110-115 mg/dL (6.1-6.4 mmol/L). Optimized settings: ISF x TDI ≤1500, I:C Ratio x TDI ≤350. RF-062025-00014

# Real-world insights to maximize TIR with Omnipod 5

Real-world data demonstrated the following settings can help to achieve optimal TIR<sup>1</sup>

## OPTIMIZED SETTINGS

| Setting                 | Optimized Value            | Impact                                         |
|-------------------------|----------------------------|------------------------------------------------|
| 1 Target Glucose        | 110 mg/dL (lowest setting) | Maximizes algorithm responsiveness             |
| 2 Insulin to Carb Ratio | ≤350/TDI                   | Optimize postprandial glycemia                 |
| 3 Correction Factor     | ≤1500/TDI                  | Improve efficacy of user-initiated corrections |

Leverage optimized settings for your Omnipod 5 patients: Small changes can lead to big improvements.

References:

1. Retrospective RWE data on file. 2025. Results shown for users with optimized settings including sufficient CGM data (≥75% of days with ≥220 readings), ≥90% time in Automated Mode, ≥5 bolus/day and an average Target Glucose of 110-115 mg/dL (6.1-6.4 mmol/L). Optimized settings: ISF x TDI ≤1500, I:C Ratio x TDI ≤350. RF-062025-00014. 2. Retrospective RWE for T1D (ages 2 yrs+) and T2D (ages 18 yrs+) users. Results based on users with ≥90 days CGM data and ≥75% of days with ≥220 readings available. Data on File. RF-042025-00013. 3. Data on file. T1D: Median time <70 mg/dL +0.23% (p<0.05). T2D: Median time < 70 mg/dL +0.04% (non-significant). RF-042025-00013.



Insulet Corporation • 100 Nagog Park, Acton, MA 01720 • 800-591-3455 • [omnipod.com/hcp](https://omnipod.com/hcp)

The Omnipod 5 Automated Insulin Delivery System is a single hormone insulin delivery system intended to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in persons aged 2 and older & type 2 diabetes in persons aged 18 years and older. The Omnipod 5 System is intended for single patient use. The Omnipod 5 System is indicated for use with NovoLog®, Humalog®, and Admelog®. Refer to the Omnipod 5 Automated Insulin Delivery System User Guide and [www.omnipod.com/safety](https://www.omnipod.com/safety) for complete safety information including indications, contraindications, warnings, cautions, and instructions. Warning: DO NOT use SmartAdjust technology for individuals under 2 years of age or use less than 5 U of insulin per day. DO NOT start to use the Omnipod 5 System or change settings without adequate training and guidance from a healthcare provider. Initiating and adjusting settings incorrectly can result in over-delivery or under-delivery of insulin, which could lead to hypoglycemia or hyperglycemia.

© 2025 Insulet Corporation. Omnipod, the Omnipod 5 logo and SmartAdjust are trademarks or registered trademarks of Insulet Corporation in the United States of America and other various jurisdictions. All rights reserved. All other trademarks are the property of their respective owners. The use of third party trademarks does not constitute an endorsement or imply a relationship or other affiliation.